Prestige Consumer Healthcare's roll-up strategy built a diverse brand portfolio, but revenue growth has now stagnated. At 14.8x forward earnings, PBH's valuation isn't compelling in today's market, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback